date,title,source
Oct-23-18,"Vaccinex, Inc. to Participate on a Panel and Meet with Investors at the BTIG Healthcare Conference October 25, 2018",GlobeNewswire
Nov-06-18,"Vaccinex, Inc. to Present Data on Its Semaphorin 4D Monoclonal Antibody Programs at Two Conferences Focused on Cancer Immunotherapy and Huntingtons Disease",GlobeNewswire
Nov-12-18,"Vaccinex, Inc. Presents Overview of the Clinical Development of VX15 (pepinemab) for the Potential Treatment of Huntingtons Disease at the Huntington Study Groups 2018 Annual Meeting",GlobeNewswire
Nov-13-18,Vaccinex Reports Third Quarter 2018 Financial Results and Provides Corporate Update,GlobeNewswire
Nov-15-18,"Vaccinex, Inc. Gives Podium Presentation and Poster at the Society for Immunotherapy of Cancer Annual Meeting",GlobeNewswire
Nov-27-18,"Vaccinex, Inc. to Present at the 11th Annual LD Micro Main Event",ACCESSWIRE
Dec-12-18,"Do Insiders Own Lots Of Shares In Vaccinex, Inc. (NASDAQ:VCNX)?",Simply Wall St.
Dec-12-18,"Preclinical Data on Vaccinex, Inc. Anti-SEMA4D Monoclonal Antibody in Combination with Checkpoint Inhibitors Published in Cancer Immunology Research",GlobeNewswire
Jan-16-19,"Vaccinex, Inc. Announces Completion of Enrollment for Its SIGNAL Huntingtons Disease Trial",GlobeNewswire
Jan-17-19,"Vaccinex, Inc. Presented Previously Disclosed Data from Ongoing Phase 1/2 Trial of VX15/2503 (Pepinemab) in Huntingtons Disease (the SIGNAL Trial) at Cambridge Healthtech Institutes 18th Annual PepTalk",GlobeNewswire
